Literature DB >> 33899929

Development and validation of nomograms predicting cancer-specific survival of vulvar cancer patients: based on the Surveillance, Epidemiology, and End Results Program.

Jin Liu1, Mengqiao Wang1.   

Abstract

OBJECTIVE: To explore potential prognostic factors and develop nomograms to predict the cancer-specific survival of patients with vulvar squamous cell carcinoma (SCC) and patients with vulvar melanoma.
METHODS: Cases of vulvar SCC and melanoma were retrieved from the Surveillance, Epidemiology, and End Results (SEER) Program, and randomly segregated into training and test sets. Based on the training set, univariate and multivariate Cox proportional hazard regressions evaluate the association between key demographic/clinical characteristics and vulvar cancer survival. Potential prognostic factors were included to construct nomograms for the prediction of 3-year and 5-year survival probabilities.
RESULTS: Age, tumor size, stage, surgery, and chemotherapy were potential factors associated with vulvar cancer survival. The C-indices for the training and test sets were 0.82 and 0.81 for SCC, and 0.73 and 0.70 for melanoma. Calibration curves revealed correlated agreements between nomogram-based probability and actual survival status.
CONCLUSION: Nomograms were developed to predict cancer-specific survival of patients with vulvar cancer, accordingly identifying the subgroup at high risk of cancer-specific mortality.
© 2021 International Federation of Gynecology and Obstetrics.

Entities:  

Keywords:  cancer-specific survival; melanoma; nomogram; squamous cell carcinoma

Mesh:

Year:  2021        PMID: 33899929     DOI: 10.1002/ijgo.13722

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  1 in total

1.  Developing and Validating Novel Nomograms for Predicting the Overall Survival and Cancer-Specific Survival of Patients With Primary Vulvar Squamous Cell Cancer.

Authors:  Weili Zhou; Yangyang Yue
Journal:  Front Med (Lausanne)       Date:  2021-12-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.